GlassScriptPhysician profile
Rakesh Shah
NPI 1851495428
$1,537.58
in general payments reported to CMS, 2019-2025
14 companies · $591 in 2025
The $591 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.31 · 2020: $13.28 · 2021: $15.88 · 2022: $104 · 2023: $338 · 2024: $404 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $474.60 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $381.87 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $283.57 | 2019-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.25 | 2020-2024 | Xifaxan |
| Lilly USA, LLC | $58.52 | 2025 | Omvoh |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.20 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.65 | 2023-2025 | Entyvio |
| Madrigal Pharmaceuticals | $34.94 | 2025 | Rezdiffra |
| Teva Pharmaceuticals USA, INC. | $27.97 | 2022-2024 | Uzedy |
| Janssen Biotech, INC. | $24.66 | 2023 | Remicade, Stelara, Simponi Aria |
| Ardelyx, INC. | $24.45 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $18.19 | 2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $17.02 | 2024 | |
| Shire North American Group INC | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.